Finoriq research workspace
SpyGlass Pharma, Inc. (SGP) Historical Metrics
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery. Review SGP valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
- Company
- SpyGlass Pharma, Inc. (SGP)
- Ticker
- SGP
- Market Cap
- $667.8M
- Latest Price
- $19.98
- Industry
- Medical Devices
SpyGlass Pharma, Inc. (SGP) Current Valuation Metrics
Static valuation preview for SpyGlass Pharma, Inc. (SGP). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -5.9% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -4.9% | Operating Cash Flow | TTM FY 2025 |
| Price / BookMarket cap divided by stockholders' equity. | 2.69x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.